Get access

UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?

Authors


  • See editorial by Winter et al., on page 4.

R. Luengo-Fernandez, Health Economics Research Centre, Department of Public Health, Old Road Campus, University of Oxford, Oxford OX3 7LF, UK (tel.: 44 1865289264; fax: 44 18652 89271; e-mail: ramon.luengo-fernandez@dph.ox.ac.uk).

Abstract

Background and purpose:  A UK government review recommended that the impact of disease on the population and economy should be assessed to inform health research priorities. This study aims to quantify UK governmental and charity research funding for dementia, cancer, coronary heart disease (CHD) and stroke in 2007/08 and assess whether the levels of research expenditure are aligned with disease and economic burden.

Methods:  We identified UK governmental agencies and charities providing health research funding and determined their levels of funding for dementia, cancer, CHD and stroke. Research funding levels were compared to the number of cases, disability-adjusted life years (DALYs) and economic burden. Economic costs were estimated using data on morbidity, mortality, health and social care use, private costs and other related indicators.

Results:  Research funding to the four diseases was £833 million, of which £590 million (71%) was devoted to cancer, £169 million (20%) to CHD, £50 million (6%) to dementia and £23 million (4%) to stroke. Cancer received £482 in research funding per 1000 DALYs lost, CHD received £266, dementia received £166, with stroke receiving £71. In terms of economic burden, for every £1 million of health and social care costs attributable to each disease, cancer received £129 269 in research funding, CHD received £73 153, stroke received £8745 and dementia received £4882.

Conclusions:  Most health research funding in the UK is currently directed towards cancer. When compared to their burden, our analysis suggests that research spending on dementia and stroke is severely underfunded in comparison with cancer and CHD.

Get access to the full text of this article

Ancillary